7SAD image
Deposition Date 2021-09-22
Release Date 2022-07-20
Last Version Date 2025-06-04
Entry Detail
PDB ID:
7SAD
Title:
Memantine-bound GluN1a-GluN2B NMDA receptors
Biological Source:
Source Organism:
Host Organism:
Method Details:
Experimental Method:
Resolution:
3.96 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:Glutamate receptor ionotropic, NMDA 1
Gene (Uniprot):Grin1
Chain IDs:A, C
Chain Length:847
Number of Molecules:2
Biological Source:Rattus norvegicus
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:Glutamate receptor ionotropic, NMDA 2B
Gene (Uniprot):Grin2b
Chain IDs:B, D
Chain Length:883
Number of Molecules:2
Biological Source:Rattus norvegicus
Primary Citation
Structural insights into binding of therapeutic channel blockers in NMDA receptors.
Nat.Struct.Mol.Biol. 29 507 518 (2022)
PMID: 35637422 DOI: 10.1038/s41594-022-00772-0

Abstact

Excitatory signaling mediated by N-methyl-D-aspartate receptor (NMDAR) is critical for brain development and function, as well as for neurological diseases and disorders. Channel blockers of NMDARs are of medical interest owing to their potential for treating depression, Alzheimer's disease, and epilepsy. However, precise mechanisms underlying binding and channel blockade have remained limited owing to challenges in obtaining high-resolution structures at the binding site within the transmembrane domains. Here, we monitor the binding of three clinically important channel blockers: phencyclidine, ketamine, and memantine in GluN1-2B NMDARs at local resolutions of 2.5-3.5 Å around the binding site using single-particle electron cryo-microscopy, molecular dynamics simulations, and electrophysiology. The channel blockers form different extents of interactions with the pore-lining residues, which control mostly off-speeds but not on-speeds. Our comparative analyses of the three unique NMDAR channel blockers provide a blueprint for developing therapeutic compounds with minimal side effects.

Legend

Protein

Chemical

Disease

Primary Citation of related structures